Company Encyclopedia
View More
name
MetaVia
MTVA.US
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc.
1.913 T
MTVA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Metavia Inc. Announces 1-for-11 Reverse Stock Split

    Metavia Inc. announced a 1-for-11 reverse stock split effective December 4, 2025, reducing outstanding shares from 25.4 million to 2.3 million. Trading on Nasdaq under symbol "MTVA" will be split-adjusted from December 5, 2025. No change to total authorized shares.

    Reuters·
    US
    MTVA
    +40.80%
    Reuters·
    US
    MTVA
    +40.80%

    MetaVia Seeks Extension to Regain Nasdaq Compliance

    MetaVia Inc. received a notice from Nasdaq for non-compliance with the minimum bid price requirement, as its stock price was below $1.00 for 30 days. The company requested a 180-day extension to regain compliance, considering a reverse stock split. Analysts rate MTVA stock as a Buy with a $5.00 target, but Spark's AI Analyst rates it as Underperform due to poor financial performance and high-risk profile.

    Tip Ranks·
    US
    MTVA
    +40.80%
    Tip Ranks·
    US
    MTVA
    +40.80%

    Metavia Inc. Faces Nasdaq Delisting Risk Over $1 Minimum Bid Price Requirement

    Metavia Inc. is at risk of being delisted from Nasdaq due to its stock trading below $1 for 30 consecutive days. The company has until May 26, 2026, to comply with the minimum bid price requirement, potentially through a reverse stock split. Failure to comply could result in delisting.

    Reuters·
    US
    MTVA
    +40.80%
    Reuters·
    US
    MTVA
    +40.80%

    MetaVia Inc. Reports Q3 2025 Financial Results

    MetaVia Inc. reported its Q3 2025 financial results, highlighting progress in clinical trials for obesity and MASH treatments. The company dosed its first patient in a Phase 1 trial for DA-1726 and noted promising results for vanoglipel in a Phase 2a trial. Financially, MetaVia posted a net loss of $3.4 million, down from $5.7 million the previous year, with $14.3 million in cash to fund operations into 2026. The company plans to advance its clinical programs and expects further data releases by the end of 2025.

    Tip Ranks·
    US
    MTVA
    +40.80%
    Tip Ranks·
    US
    MTVA
    +40.80%

    MetaVia’s Strategic Positioning and Promising Drug Candidates Drive Buy Rating

    H.C. Wainwright analyst Andrew Fein has reiterated a Buy rating on MetaVia, setting a price target of $12.00. This rating is supported by MetaVia's strategic positioning in metabolic diseases and promising drug candidates DA-1726 and DA-1241. The company is pursuing partnerships to develop DA-1241 alongside liver-directed therapies, enhancing its competitive edge. Positive early trial results for DA-1726 and favorable FDA trends suggest accelerated development and growth potential. Additionally, Maxim Group also maintains a Buy rating with a $5.00 price target.

    Tip Ranks·
    US
    MTVA
    +40.80%
    Tip Ranks·
    US
    MTVA
    +40.80%
    © 2025 Longbridge｜Disclaimer